RT Journal Article
SR Electronic
T1 Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.01.20047381
DO 10.1101/2020.04.01.20047381
A1 Herold, Tobias
A1 Jurinovic, Vindi
A1 Arnreich, Chiara
A1 Hellmuth, Johannes C.
A1 von Bergwelt-Baildon, Michael
A1 Klein, Matthias
A1 Weinberger, Tobias
YR 2020
UL http://medrxiv.org/content/early/2020/04/04/2020.04.01.20047381.abstract
AB The pandemic Coronavirus-disease 19 (COVID-19) is characterized by a heterogeneous clinical course. While most patients experience only mild symptoms, a relevant proportion develop severe disease progression with increasing hypoxia up to acute respiratory distress syndrome. The substantial number of patients with severe disease have strained intensive care capacities to an unprecedented level. Owing to the highly variable course and lack of reliable predictors for deterioration, we aimed to identify variables that allow the prediction of patients with a high risk of respiratory failure and need of mechanical ventilationPatients with PCR proven symptomatic COVID-19 infection hospitalized at our institution from 29th February to 27th March 2020 (n=40) were analyzed for baseline clinical and laboratory findings. Patients requiring mechanical ventilation 13/40 (32.5%) did not differ in age, comorbidities, radiological findings, respiratory rate or qSofa score. However, elevated interleukin-6 (IL-6) was strongly associated with the need for mechanical ventilation (p=1.2·10−5). In addition, the maximal IL-6 level (cutoff 80 pg/ml) for each patient during disease predicted respiratory failure with high accuracy (p=1.7·10−8, AUC=0.98). The risk of respiratory failure for patients with IL-6 levels of ≥ 80pg /ml was 22 times higher compared to patients with lower IL-6 levels.In the current situation with overwhelmed intensive care units and overcrowded emergency rooms, correct triage of patients in need of intensive care is crucial. Our study shows that IL-6 is an effective marker that might be able to predict upcoming respiratory failure with high accuracy and help physicians correctly allocate patients at an early stage.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe note that patient data can be made available from the authors upon reasonable request and with permission of the local ethics committee.